NLRP3 and left ventricular hypertrophy: Pirfenidone can regulate the ROS-dependent NLRP3-IL-1β signaling pathway by inhibiting NLRP3, improving left ventricular hypertrophy and myocardial fibrosis in rats with TAC (93).